Cirrhosis News and Research

Latest Cirrhosis News and Research

Many Canadian territories restrict access to medications for treating hepatitis C, study finds

A study conducted by Canadian and Australian researchers shows that nearly everywhere in Canada, the provinces and territories impose obstacles to reimbursement of new direct-acting antivirals (DAA) to treat hepatitis C by because of their cost.

14 Oct 2016

Japanese researchers identify mechanism for hormone that limits liver fibrosis

Nonalcoholic steatohepatitis (NASH) has been emerging worldwide and effective treatment, especially for liver fibrosis, is essential for improving the prognosis.

13 Oct 2016

Common drug for allergies and asthma could prevent fibrosis, reduce need for liver transplants

A drug commonly used for the prevention of allergies and asthma someday could find new use in preventing liver disease and reducing the need for transplants, according to new research published in the October 2016 edition of the scientific journal Hepatology.

12 Oct 2016

Novel method can quantify progression of NAFLD to more advanced fibrosis and cirrhosis

Combining multiple non-invasive measures, researchers at University of California San Diego School of Medicine describe a novel method to quantify the progression of nonalcoholic fatty liver disease (NAFLD) to its more dangerous and deadly states — advanced fibrosis and cirrhosis.

12 Oct 2016

New non-invasive method could improve diagnosis of severe liver disease

A new non-invasive method of predicting the risk of developing a severe form of liver disease could ensure patients receive early and potentially life-saving medical intervention before irreversible damage is done.

6 Oct 2016

Bile acid transporter inhibitors can prevent NASH in mice, study shows

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of Atlanta have shown.

21 Sep 2016

UofL investigators to explore liver disease in comprehensive fashion

Liver diseases are clinically important health problems and are generally underappreciated. The University of Louisville has brought together a critical mass of investigators to study liver diseases in a comprehensive fashion.

14 Sep 2016

Experts recommend removal of restrictions in accessing new hepatitis C therapies for drug users

Global health experts are today are calling for the removal of restrictions preventing people who use drugs from accessing new hepatitis C cures. So long as these restrictions exist, the goal of disease elimination will remain out of reach, they say.

7 Sep 2016

New discovery could potentially lead to treatments for Crohn's disease

Scientists at the University of British Columbia have made a discovery that could potentially lead to treatments for a debilitating complication of Crohn's disease.

2 Sep 2016

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Food provides us with a variety of substances we need to maintain life. These substances are essential nutrients and are classified as macronutrients (water, protein, fats, and carbohydrates) and micronutrients (vitamins and minerals).

22 Aug 2016

Hydrothermal DMR results show promise in treatment of type 2 diabetes

Fractyl Laboratories Inc. (Fractyl) announced today publication of data in the current issue of Diabetes Care from the Company’s first-in-human study of RevitaTM duodenal mucosal resurfacing (Revita DMR).

17 Aug 2016

Increased treatment for HCV in Rhode Island could help eradicate disease by 2030

A new Brown University study projects that increasing the number of Rhode Islanders treated every year for hepatitis C virus infection (HCV) to about 2,000 by 2020 would reduce cases by 90 percent and prevent more than 70 percent of expected liver-related deaths in the state by 2030.

5 Aug 2016

Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

Studies have shown that obstructive sleep apnea and low nighttime oxygen, which result in oxidative stress, are associated with the progression of non-alcoholic fatty liver disease (NAFLD) in adults.

5 Aug 2016

New report urges all European countries to adopt universal vaccination for hepatitis

To coincide with World Hepatitis Day, a new report, commissioned by United European Gastroenterology, calls for all European countries to adopt universal vaccination and harmonised screening programmes for hepatitis, as well as improved neonatal screening, to help speed up the eradication of the disease.

1 Aug 2016

New screen-and-treat programme for hepatitis B may thwart deadly complications of disease

Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus.

27 Jul 2016

Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Patients suffering from liver cirrhosis often die of life-threatening bacterial infections. In these patients the immune cells are unable to eliminate the bacterial infections.

19 Jul 2016

Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Chronic liver disease (CLD) and cirrhosis are serious liver conditions but little is known about how they affect ethnic minority populations in the United States.

19 Jul 2016

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.

6 Jul 2016

FIB-4 index predicts HBV-related HCC

Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.

4 Jul 2016

Targeted molecular therapy reduces initial development of NAFLD in mice

Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease.

1 Jul 2016

Cirrhosis News and Research

Latest Cirrhosis News and Research

Many Canadian territories restrict access to medications for treating hepatitis C, study finds

Japanese researchers identify mechanism for hormone that limits liver fibrosis

Common drug for allergies and asthma could prevent fibrosis, reduce need for liver transplants

Novel method can quantify progression of NAFLD to more advanced fibrosis and cirrhosis

New non-invasive method could improve diagnosis of severe liver disease

Bile acid transporter inhibitors can prevent NASH in mice, study shows

UofL investigators to explore liver disease in comprehensive fashion

Experts recommend removal of restrictions in accessing new hepatitis C therapies for drug users

New discovery could potentially lead to treatments for Crohn's disease

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Hydrothermal DMR results show promise in treatment of type 2 diabetes

Increased treatment for HCV in Rhode Island could help eradicate disease by 2030

Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

New report urges all European countries to adopt universal vaccination for hepatitis

New screen-and-treat programme for hepatitis B may thwart deadly complications of disease

Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

FIB-4 index predicts HBV-related HCC

Targeted molecular therapy reduces initial development of NAFLD in mice

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in